A Multicenter Pharmacoepidemiological Cohort on Real Life Use of Semaglutide in Adolescents or Adults With Monogenic Obesity

Rare genetic forms of obesity, so called monogenic obesity are linked to alteration in energy balance involving hypothalamic pathways. More than 60 genes encoding for proteins located in the hypothalamic leptin/melanocortin pathway have been described in the French National Protocol for Diagnostic and Care (PNDS) https://www.has-sante.fr/jcms/p\_3280217/fr/generique-obesites-de-causes-rares).

While pathogenic and likely pathogenic variants in these genes are well-established causes of monogenic obesity, current evidence supports a broader genetic architecture of obesity, better understood as a continuum ranging from rare high-impact variants to polygenic susceptibility.

Variants of uncertain significance (VUS) as well as variants currently classified as benign or likely benign are frequently identified in clinical practice, and their classification may evolve over time as genomic databases expand and functional data accumulate In addition, polygenic background may interact with rare variants and contribute to the severity of the phenotype, disease progression, and therapeutic response.

The natural history of monogenic obesity is characterized by an early onset in childhood, with a major increase in weight in adolescence and young adulthood. The worsening of obesity exposes these patients to severe complications. Severe obesity and eating disorders have a major impact on the quality of life of the person but also of the family and caregivers. Clinical management is complex and requires comprehensive, specialized and multidisciplinary management. The usual lifestyle approaches have so far shown disappointing results, similarly to bariatric surgery which leads to a more frequent weight regain in the situation of monogenic obesity, justifying new approaches.

In this context, evaluating the response to treatment in the particular condition of monogenic obesity is crucial to propose therapeutic options as early as possible to limit weight evolution and its complications.

GLP-1 based innovative therapies have recently emerged as a promising option for treatment of obesity and its complications. This is the case for Semaglutide marketed as OZEMPIC® and WEGOVY®, developed by Novo Nordisk. However, there is a lack of data to confirm that semaglutide could be also effective in monogenic obesity, particularly across the full spectrum of genetic variants involved in the leptin-melanocortin pathway.

In France, semaglutide is currently accessible through several regulatory frameworks:

OZEMPIC® (up to 2 mg/week) is reimbursed by the French Social Security for the treatment of type 2 diabetes in adult patients.

WEGOVY® (up to 2.4 mg/week) was available through an Early Access Programme from May 2022 to September 2024 for adults with BMI \>40 kg/m² and at least one comorbidity. Treatment initiated in this framework can be continued until December 2025.

Since November 2024, WEGOVY® (up to 2.4 mg/week) has had marketing authorization for the treatment of adolescents and adults ≥12 years with BMI ≥30 kg/m². However, the drug is not yet reimbursed, except in rare cases through individual exceptional reimbursement for rare and complex diseases.

Given this evolving regulatory landscape, it is essential to assess the real-life efficacy and safety of semaglutide in individuals with including both adolescents and adults carrying variants across the continuum of genetic susceptibility.

The aim of the ObGeSema project is to set up a cohort composed of patients (1) having already initiated a treatment and (2) newly treated by Semaglutide in 21 pediatric and adult Specialized Obesity Centres (CSOs) and describe their evolution over a 4 years follow-up.

• Change in weight and Body Mass Index (BMI) [Срок оценки: From baseline (T0) to 6 and/or 24 and/or 36 and/or 48 and/or 60 months]
• Reduction of body weight equal to or above 5% [Срок оценки: From baseline (T0) to 6 and/or 12 and/or 24 and/or 36 and/or 48 and/or 60 months]
• Change in Hunger score [Срок оценки: From baseline (T0) to 12 and/or 24 and/or 36 and/or 48 and/or 60 months]
• Change in eating behaviour measured by Food Craving questionnaire [Срок оценки: From baseline (T0) to 12 months]
• Change in eating behaviour measured by the Binge Eating Scale (BES) [Срок оценки: From baseline (T0) to 12 months]
• Change in eating behaviour measured by the Dutch Eating Behaviour Questionnaire (DEBQ) [Срок оценки: From baseline (T0) to 12 months]
• Change in eating behaviour measured by the Dykens questionnaire for ≥18 years patients [Срок оценки: From baseline (T0) to 12 months]
• Change in eating behaviour measured by the Child Eating Behaviour Questionnaire (CEBQ) [Срок оценки: From baseline (T0) to 12 months]
• Change in the International physical activity questionnaire (IPAQ - short form) for ≥18 years patients [Срок оценки: From baseline (T0) to 12 months]
• Change in Digestive disorders (GIQLI ) for ≥18 years patients [Срок оценки: From baseline (T0) to 12 and/or 24 and/or 36 and/or 48 and/or 60 months]
• Change in score of quality of life scores (patient and parents) for ≥18 years patients [Срок оценки: From baseline (T0) to 12 months]
• Change in sleep disorder (MCTQ score) for ≥18 years patients [Срок оценки: From baseline (T0) to 12 months]